Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

NeuroRestore - a novel therapy for Alzheimer´s disease

Reference number
Coordinator AlzeCure Pharma AB
Funding from Vinnova SEK 500 000
Project duration October 2017 - May 2018
Status Completed

Purpose and goal

Alzheimer´s disease (AD) is the most common form of dementia and one of the most devastating the diseases we face today from a socio-economic perspective. AlzeCure Pharma is a Swedish pharmaceutical company whose goal is to develop NeuroRestore, one innovative symptomatic drug therapy with disease modifying potential for the treatment of AD. We have used the funding to do a comprehensive feasibility study where we have developed a business plan to guide the project towards clinical validation and subsequent commercialization of the therapy.

Expected effects and result

The feasibility study has demonstrated strong clinical and commercial potential of NeuroRestore. We have found that the increasing prevalence of AD and other cognitive disorders, coupled with the need for novel symptomatic therapies with innovative mechanisms of action to the AD market, create a unique business opportunity for AlzeCure. NeuroRestore has the potential to become a real game changer in the area of cognitive disorders.

Planned approach and implementation

During the reporting period, we have conducted a feasibility study where we worked in parallel with both databases and external parties to develop a comprehensive analysis of the indication area, commercial opportunities and clinical plan.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 19 May 2019

Reference number 2017-05095

Page statistics